VERZENIO

This brand name is authorized in United States. It is also authorized in Australia, Canada, Ecuador, Hong Kong SAR China, Israel, Japan, Singapore, South Africa.

Active ingredients

The drug VERZENIO contains one active pharmaceutical ingredient (API):

1	Abemaciclib UNII 60UAB198HK - ABEMACICLIB
	Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), and most active against Cyclin D1/CDK4 in enzymatic assays. Abemaciclib prevents retinoblastoma protein (Rb) phosphorylation, blocking cell cycle progression from the G1 to the S-phase of cell division, leading to suppression of tumour growth.
	Read more about Abemaciclib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VERZENIOS Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EF03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EF Cyclin-dependent kinase (CDK) inhibitors
Discover more medicines within L01EF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11868P, 11871T, 11876C
CA	Health Products and Food Branch	02487098, 02487101, 02487128, 02487136
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5330-MEE-0720, 5435-MEE-0820, 5549-MEE-1020
HK	Department of Health Drug Office	66494, 66495, 66496
IL	מִשְׂרַד הַבְּרִיאוּת	8334, 8335, 8336
JP	医薬品医療機器総合機構	4291054F1026, 4291054F2022, 4291054F3029
SG	Health Sciences Authority	15788P, 15789P, 15790P
US	FDA, National Drug Code	0002-4483, 0002-4815, 0002-5337, 0002-6216
ZA	Health Products Regulatory Authority	53/26/0434, 53/26/0435, 53/26/0436, 53/26/0437